Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984174 | 0.85 | HPGD (0.38) | HPGDMAPTMYCALDH1A1GAA | |
| SCHEMBL7974836 | 0.83 | RBP4 (0.41) | HPGDMAPTALDH1A1GAAKDM4E | |
| SCHEMBL6800970 | 0.78 | HSD11B1 (0.40) | HPGDMAPTALDH1A1POLBTSHR | |
| SCHEMBL7188174 | 0.67 | EDNRA (0.42) | HPGDMAPTALDH1A1 | |
| SCHEMBL7263685 | 0.65 | CTDSP1 (0.42) | HPGDMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL7091506 | 0.64 | CA2 (0.42) | MAPTALDH1A1POLB | |
| SCHEMBL6542406 | 0.63 | HSD11B1 (0.51) | HPGDLMNAKDM4E | |
| SCHEMBL11701961 | 0.63 | CA2 (0.41) | MAPTLMNAALDH1A1POLB | |
| SCHEMBL7973834 | 0.62 | SLC40A1 (0.40) | LMNAALDH1A1KDM4ETSHR | |
| SCHEMBL7234625 | 0.58 | NR3C2 (0.45) | HPGDMAPTLMNAMYCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | HPGD 1103/4885MAPT 2338/4885LMNA 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.